Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Hold rating on Intec Pharma (NTEC) today and set a price target of $0.50. The company’s shares closed last Monday at $0.52, close to its 52-week low of $0.41.
According to TipRanks.com, Higgins is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.6% and a 30.6% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Rhythm Pharmaceuticals.
Currently, the analyst consensus on Intec Pharma is a Hold with an average price target of $0.85, implying a 70.0% upside from current levels. In a report issued on December 2, H.C. Wainwright also reiterated a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.25 and a one-year low of $0.41. Currently, Intec Pharma has an average volume of 1.08M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
